Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novamind Inc
(OP:
NVMDF
)
N/A
UNCHANGED
Last Price
Updated: 3:36 PM EDT, Jun 13, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novamind Inc
< Previous
1
2
Next >
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
December 08, 2021
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics...
Via
Benzinga
Topics
Death
Exposures
Death
Novamind Opens Addiction Clinic In Utah, Establishing Substance Use Disorder Program
December 06, 2021
Novamind Inc. (OTCQB:NVMDF),...
Via
Benzinga
Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders
December 02, 2021
Novamind Inc. (OTCQB:NVMDF) a mental health compan...
Via
Benzinga
Psychedelic Medicine: Major Health Providers Including Blue Cross Now Cover Ketamine Treatments
November 18, 2021
Four major health insurance providers recently approved psychedelic medicine company Novamind Inc. (CSE:
Via
Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
November 04, 2021
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat?
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
October 23, 2021
The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last.
Via
Talk Markets
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
October 11, 2021
The Week In Psychedelics
Via
Benzinga
Psychedelic Medicine For End-Of-Life And Palliative Care Patients: Novamind Launches Treatment Program
October 07, 2021
Novamind (Canadian: NM) (OTCQB:NVMDF), a company in the ps...
Via
Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
October 04, 2021
The Week In Psychedelics:
Via
Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
September 09, 2021
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...
Via
Benzinga
Psychedelic Drug Industry Report Card For 2021
September 01, 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development.
Via
Talk Markets
Which Psychedelic Drug Has The Most Commercial Potential?
August 10, 2021
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.
Via
Talk Markets
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
August 02, 2021
Last week in Psychedelics:
Via
Benzinga
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
June 14, 2021
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Video: Experts Discuss Use Of Psychedelics In Mental Health Settings
May 11, 2021
The psychedelics industry has started to gain serious traction and is attracting lots of attention these days. However, what many people may not kn...
Via
Benzinga
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
May 10, 2021
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound...
Via
Benzinga
Novamind And Field Trip Expand Footprint Of Psychedelic Clinics
May 05, 2021
Novamind Inc. (OTC:NVMDF), a company specializing in mental ...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.